Prestige Biopharma Presents Clinical Research Results of Pancreatic Cancer Antibody Drug at AACR in the US

Prestige BioPharma, a pharmaceutical company specializing in antibody biopharmaceuticals, announced on the 11th that it will participate in the '2024 American Association for Cancer Research (AACR 2024)' held in San Diego, USA, from the 5th to the 10th of next month, presenting two poster presentations including clinical data related to the Phase 1/2a trial of the pancreatic cancer antibody drug PBP1510. AACR is considered one of the world's top three cancer conferences alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).

In particular, the first presentation will showcase for the first time the protocol and progress of the ongoing Phase 1/2a clinical trial of PBP1510 being conducted in five countries including the United States and Europe. PBP1510 is a first-in-class antibody drug that treats pancreatic cancer by neutralizing the PAUF protein, which is overexpressed in more than 80% of pancreatic cancer patients. As of March, 10 out of 30 patients in the Phase 1 clinical trial have completed dosing. All surviving patients have experienced no adverse reactions since dosing, and the trial is progressing smoothly. Since the start of the clinical trial last year, patient recruitment has accelerated, speeding up Phase 1 dosing.

The second presentation will cover the mechanism by which the target protein CTHRC1 of PBP1710 acts in the progression of pancreatic cancer. Pancreatic cancer is characterized by the activation of stellate cells, proliferation of inflammatory cells and cancer-associated fibroblasts around cancer cells, and hyperplasia of connective tissue due to secretion of collagen and other substances. Through research, the company has for the first time identified that the CTHRC1 protein activates pancreatic stellate cells, which induce fibrosis of connective tissue?a histological characteristic of pancreatic cancer?into a specific subtype of cancer-associated fibroblasts.

A representative of Prestige BioPharma stated, "At this year's AACR in the United States, we will present research results aimed at conquering pancreatic cancer, which has the lowest response rate to anticancer treatments and no targeted therapies, through PBP1510 and PBP1710." They added, "In particular, PBP1510, which has entered clinical trials, plans to operate a two-track strategy aiming for rapid product approval by utilizing various fast-track support systems including the FDA's rolling review function, while simultaneously progressing clinical trials."

Meanwhile, PBP1510 is a pancreatic cancer antibody drug that received Fast Track designation from the U.S. FDA last year. Fast Track is a program that provides comprehensive support from the FDA to expedite drug development and review when there are no existing treatments or when superior effects are expected for serious diseases such as pancreatic cancer, which ranks third in cancer deaths in the United States. Through this, Prestige BioPharma plans to accelerate commercialization by utilizing Accelerated Approval and Priority Review systems as soon as meaningful results are obtained from the ongoing Phase 1/2a clinical trial.